Open AccessNew Drugs for Myeloma
Author(s) -
Richardson Paul G.,
Mitsiades Constantine,
Schlossman Robert,
Munshi Nikhil,
Anderson Kenneth
Publication year - 2007
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.12-6-664
Subject(s) - thalidomide , lenalidomide , medicine , bortezomib , multiple myeloma , dexamethasone , regimen , proteasome inhibitor , oncology , pharmacology , pomalidomide , combination therapy
Learning Objectives After completing this course, the reader will be able to: Discuss the impact of novel agents on the treatment paradigm for multiple myeloma. Explain the importance of combination regimens and in particular the ability to rechallenge patients with a combination of drugs that may each have been administered separately before. Describe the toxicity profiles of the agents being used with a focus on key side effects and discuss the potential value of these agents in special populations, such as those with renal failure.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com